PREDICTING VITILIGO TREATMENT RESPONSE THROUGH EARLY IMMUNE SHIFTS
Managing nonsegmental vitiligo remains one of the most challenging tasks in dermatology: even with standard therapy, visible repigmentation is slow to appear, and predicting who will truly respond to treatment is difficult. In a prospective study published in the Journal of Investigative Dermatology (2026), the authors compared early changes in the skin and blood with 6-month outcomes. They demonstrated that a decrease in specific populations of tissue-resident memory T cells, Tr1 cells, and the FABP4 protein could serve as potential markers of response. We explore what the researchers measured, which signals were linked to repigmentation, and how this data can benefit practitioners. Research breakdown and clinical insights are in our editorial note.